{
    "organizations": [],
    "uuid": "3104ce04209d24c4a3fdfb2a5b846a54dd40250e",
    "author": "",
    "url": "https://www.reuters.com/article/brief-aclaris-therapeutics-signs-agreeme/brief-aclaris-therapeutics-signs-agreement-with-james-alexander-corp-idUSFWN1PP1EY",
    "ord_in_thread": 0,
    "title": "BRIEF-Aclaris Therapeutics Signs Agreement With James Alexander Corp",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 30 (Reuters) - Aclaris Therapeutics Inc:\n* ACLARIS THERAPEUTICS SAYS ON JAN 24, CO ENTERED INTO COMMERCIAL SUPPLY MANUFACTURING SERVICES AGREEMENT WITH JAMES ALEXANDER CORP - SEC FILING\n* ACLARIS THERAPEUTICS INC - PURSUANT TO AGREEMENT, COMPANY MUST MEET A PRODUCT UNIT PURCHASE MINIMUM EACH YEAR BETWEEN 2018 AND 2022\n* ACLARIS THERAPEUTICS INC - DURING TERM OF AGREEMENT, JAMES ALEXANDER WILL NOT MANUFACTURE ANY COMPETITIVE PRODUCT, AS DEFINED IN AGREEMENT\n* ACLARIS-JAMES ALEXANDER TO EXCLUSIVELY MANUFACTURE FINISHED DOSAGE FORM OF CO‘S FDA-APPROVED ESKATA TOPICAL SOLUTION, 40% (W/W) PRODUCT FOR SALE\n* ACLARIS THERAPEUTICS - UNDER DEAL, GRANTED JAMES ALEXANDER ROYALTY-FREE, NON-EXCLUSIVE, NON-TRANSFERRABLE LICENSE OF CERTAIN OF INTELLECTUAL PROPERTY\n* ACLARIS THERAPEUTICS- IN EVENT THAT CO NOT MEET PURCHASE MINIMUM REQUIRED UNDER DEAL, JAMES ALEXANDER‘S EXCLUSIVITY OBLIGATION TO CO WILL CEASE\n* ACLARIS-AGREEMENT IS FIVE YEARS FROM THE DATE OF THE FIRST COMMERCIAL SALE OF ESKATA, THEREAFTER TO BE RENEWED AUTOMATICALLY FOR ONE-YEAR PERIODS Source text - bit.ly/2GwHMRp Further company coverage:\n ",
    "published": "2018-01-30T23:57:00.000+02:00",
    "crawled": "2018-01-31T00:11:34.019+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "aclaris",
        "therapeutic",
        "inc",
        "aclaris",
        "therapeutic",
        "say",
        "jan",
        "co",
        "entered",
        "commercial",
        "supply",
        "manufacturing",
        "service",
        "agreement",
        "james",
        "alexander",
        "corp",
        "sec",
        "filing",
        "aclaris",
        "therapeutic",
        "inc",
        "pursuant",
        "agreement",
        "company",
        "must",
        "meet",
        "product",
        "unit",
        "purchase",
        "minimum",
        "year",
        "aclaris",
        "therapeutic",
        "inc",
        "term",
        "agreement",
        "james",
        "alexander",
        "manufacture",
        "competitive",
        "product",
        "defined",
        "agreement",
        "alexander",
        "exclusively",
        "manufacture",
        "finished",
        "dosage",
        "form",
        "co",
        "eskata",
        "topical",
        "solution",
        "product",
        "sale",
        "aclaris",
        "therapeutic",
        "deal",
        "granted",
        "james",
        "alexander",
        "license",
        "certain",
        "intellectual",
        "property",
        "aclaris",
        "event",
        "co",
        "meet",
        "purchase",
        "minimum",
        "required",
        "deal",
        "james",
        "alexander",
        "exclusivity",
        "obligation",
        "co",
        "cease",
        "five",
        "year",
        "date",
        "first",
        "commercial",
        "sale",
        "eskata",
        "thereafter",
        "renewed",
        "automatically",
        "period",
        "source",
        "text",
        "company",
        "coverage"
    ]
}